^
    Back
    Association details:
    Biomarker:MCL1 overexpression
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers

    Published date:
    11/06/2019
    Excerpt:
    We identified 4 additional CLL cases relapsing on venetoclax with leukemia samples collected before and after relapse. By immunohistochemical staining of 9 of 10 cases for which tissue was available, we detected increased MCL-1 expression at relapse in 6 of 9 cases (p = 0.026).
    DOI:
    10.1182/blood-2019-131336
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Identification of Recurrent Genomic Alterations in the Apoptotic Machinery in CLL Patients Treated with Venetoclax Monotherapy

    Published date:
    11/06/2019
    Excerpt:
    Comparison of mRNA expression pre- and post-VEN treatment demonstrated increased expression at the time of progression of key apoptotic genes BCL2L1 (BCL-XL), MCL1 and BCL2A1, all of which are known resistance factors to VEN.
    DOI:
    10.1182/blood-2019-127458